165 related articles for article (PubMed ID: 36058919)
1. Increased expression of METTL3 in pancreatic cancer tissues associates with poor survival of the patients.
Li Y; Huang H; Zhu Y; Xu B; Chen J; Liu Y; Zheng X; Chen L
World J Surg Oncol; 2022 Sep; 20(1):283. PubMed ID: 36058919
[TBL] [Abstract][Full Text] [Related]
2. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
3. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
4. Survival-associated N
Qu J; Wang L; Jiang M; Wei Z; Fu G; Zhang X
BMC Cancer; 2021 Nov; 21(1):1265. PubMed ID: 34814861
[TBL] [Abstract][Full Text] [Related]
5. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
Zhu D; Liu Y; Chen J; Wang Q; Li Y; Zhu Y; Feng J; Jiang J
J Transl Med; 2022 Jul; 20(1):298. PubMed ID: 35794583
[TBL] [Abstract][Full Text] [Related]
6. High Expression of CHST11 Correlates with Poor Prognosis and Tumor Immune Infiltration of Pancreatic Cancer.
Zhang P; Chen D; Cui H; Luo Q
Clin Lab; 2022 Dec; 68(12):. PubMed ID: 36546737
[TBL] [Abstract][Full Text] [Related]
7. METTL3-mediated m
Wang Q; Chen C; Ding Q; Zhao Y; Wang Z; Chen J; Jiang Z; Zhang Y; Xu G; Zhang J; Zhou J; Sun B; Zou X; Wang S
Gut; 2020 Jul; 69(7):1193-1205. PubMed ID: 31582403
[TBL] [Abstract][Full Text] [Related]
8. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Ma XX; Cao ZG; Zhao SL
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
[TBL] [Abstract][Full Text] [Related]
9. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
10. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ma Z; Li Q; Liu P; Dong W; Zuo Y
Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of scRNA-seq and bulk RNA-seq reveals that GPRC5A is an important prognostic gene in pancreatic cancer and is associated with B-cell Infiltration in pancreatic cancer.
Dong C; Ma H; Mi N; Fu W; Yi J; Gao L; Wang H; Ren Y; Lin Y; Han F; Chen Z; Zhou W
Front Oncol; 2024; 14():1283164. PubMed ID: 38634049
[TBL] [Abstract][Full Text] [Related]
12. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
Xia T; Wu X; Cao M; Zhang P; Shi G; Zhang J; Lu Z; Wu P; Cai B; Miao Y; Jiang K
Pathol Res Pract; 2019 Nov; 215(11):152666. PubMed ID: 31606241
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer.
Zhou X; Zhu X; Yao J; Wang X; Wang N
Invest New Drugs; 2021 Dec; 39(6):1469-1483. PubMed ID: 33983530
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
15. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
16. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer.
Lian S; Zhai X; Wang X; Zhu H; Zhang S; Wang W; Wang Z; Huang J
Medicine (Baltimore); 2016 Jul; 95(30):e4328. PubMed ID: 27472713
[TBL] [Abstract][Full Text] [Related]
18. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer.
Cao M; Zhang PB; Wu PF; Chen Q; Ge WL; Shi GD; Yin J; Cai BB; Cao SJ; Miao Y; Jiang KR
Biomed Res Int; 2021; 2021():6530298. PubMed ID: 33748270
[TBL] [Abstract][Full Text] [Related]
19. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
20. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
